The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone episode artwork

EPISODE · Aug 11, 2022 · 7 MIN

The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone

from Diabetes Discourse

Host: John Buse, MD, PhD Guest: David Spence, MD Pioglitazone was studied in the Insulin Resistance Intervention after Stroke trial, or IRIS for short. What do we need to know about it? Joining Dr. John Buse to share background and clinical data of the impacts observed is Dr. David Spence, a Professor Emeritus of Neurology and Clinical Pharmacology at Western University and the Director of the Stroke Prevention and Atherosclerosis Research Center in London, Ontario.

Episode metadata supplied by the publisher feed · Published Aug 11, 2022

Embed this episode

NOW PLAYING

The IRIS Trial: Reviewing Results & Taking a Look at Pioglitazone

0:00 7:30

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Diabetes Discourse?

This episode is 7 minutes long.

When was this Diabetes Discourse episode published?

This episode was published on August 11, 2022.

Can I download this Diabetes Discourse episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!